Patents by Inventor Lee A. Goodglick

Lee A. Goodglick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BIOMARKER OF LUNG CANCER
    Publication number: 20120190573
    Abstract: The present invention provides methods of providing a prognosis for a lung cancer in a subject and methods of predicting the risk of metastasis of a lung cancer in a subject. The present invention additionally provides kits that find use in the practice of the methods of the invention.
    Type: Application
    Filed: July 27, 2010
    Publication date: July 26, 2012
    Applicant: The Regents of the University of California
    Inventors: Brigitte N. Gomperts, Aik T. Ooi, Derek W. Nickerson, Lee Goodglick
  • AROMATASE EXPRESSION PREDICTS SURVIVAL IN WOMEN WITH NON-SMALL CELL LUNG CANCER
    Publication number: 20100331203
    Abstract: The present invention relates to the discovery that the level of aromatase polypeptide expression in non-small cell lung carcinomas can be used for example to provide information useful in prognostic and therapeutic methodologies in women having or suspected of having this cancer.
    Type: Application
    Filed: October 6, 2008
    Publication date: December 30, 2010
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Lee Goodglick, Richard J. Pietras, Vei Mah, David B. Seligson, David S. Chia, Diana C. Marquez-Garban, Michael C. Fishbein
  • Therapeutic and Prognostic Factor Yy1 in Human Cancer
    Publication number: 20080311039
    Abstract: The present invention provides for the first time YY1, a transcription factor gene over-expressed and/or functionally overactive in human cancer. The present invention provides methods of diagnosing and providing a prognosis for cancer such as prostate cancer, as well as methods of drug discovery. YY1 is also a therapeutic target for treatment of cancer resistant to conventional and experimental cancer therapeutics. Inhibition of YY1 expression and/or activity sensitizes resistant tumor cells to cytotoxic treatments, including chemotherapy, radiation therapy, hormonal therapy, and immunotherapy.
    Type: Application
    Filed: September 9, 2005
    Publication date: December 18, 2008
    Applicant: The Regents of the University of California
    Inventors: Benjamin Bonavida, Lee Goodglick, Hermes Gaban, Stephan Horvath, David Seligson
  • Nucleic acids for the diagnosis and treatment of giant cell arteritis
    Patent number: 6743903
    Abstract: This invention provides nucleic acids and methods for making and using them. The compositions and methods of the invention are used to diagnose and treat Giant Cell Arteritis (GCA).
    Type: Grant
    Filed: January 18, 2000
    Date of Patent: June 1, 2004
    Assignee: The Regents of the University of California
    Inventors: Lynn K. Gordon, Lee Goodglick, Melissa Goldman
  • Immunoglobulin superantigen binding to gp 120 from HIV
    Patent number: 5691135
    Abstract: VH3 and VH4 type immunoglobulins display superantigen-type binding affinity for the HIV gp120 envelope glycoprotein. VH3 and VH4 type antibody molecules, including IgG and IgM, are shown to suppress HIV infection in vivo and in vitro. Determining the level of such antibody molecules is correlated to the advancement of HIV disease state.
    Type: Grant
    Filed: September 14, 1994
    Date of Patent: November 25, 1997
    Assignee: The Regents of the University of California
    Inventors: Jonathan Braun, Lee A. Goodglick